Is it worth buying Edwards Lifesciences stock at a price of $75.17? If this question is on your mind, make sure to check out the fundamentals of this Specialty Industrial Machinery large-cap company:
-
Edwards Lifesciences has logged a 0.7% 52 week change, compared to 22.9% for the S&P 500
-
EW has an average analyst rating of buy and is -3.44% away from its mean target price of $77.85 per share
-
Its trailing earnings per share (EPS) is $2.34, which brings its trailing Price to Earnings (P/E) ratio to 32.1. The Health Care sector's average P/E ratio is 30.21
-
The company's forward earnings per share (EPS) is $2.77 and its forward P/E ratio is 27.1
-
The company has a Price to Book (P/B) ratio of 6.85 in contrast to the Health Care sector's average P/B ratio is 4.08
-
EW has reported YOY quarterly earnings growth of 14.5% and gross profit margins of 0.8%
-
The company's free cash flow for the last fiscal year was $808.4 Million and the average free cash flow growth rate is 2.0%
-
Edwards Lifesciences's revenues have an average growth rate of 6.8% with operating expenses growing at 7.4%. The company's current operating margins stand at 28.1%